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ABSTRACT

OBJECTIVE: The objective of this selective EBM review is to determine whether or not
Asenapine is more effective than other interventions in the treatment of adult patients with
bipolar I disorder.
STUDY DESIGN: Review of three English language primary randomized controlled trial
studies published from 2009-2010.
DATA SOURCES: Three randomized controlled trials studying the effectiveness of Asenapine
in the treatment of mania in adult patients with bipolar I disorder in comparison to other
interventions.
OUTCOME MEASURED: Outcomes measured were reduction in severity of manic symptoms
and tolerability of the medication. The severity of manic symptoms was measured using the
Young Mania Rating Scale (YMRS). The YMRS is a self report questionnaire completed by the
patients. It includes rating scales for elevated mood, increased motor activity and energy, sexual
interest, sleep, irritability, speech, language-thought disorder, content, disruptive-aggressive
behavior, appearance, and insight. Tolerability was based on adverse event assessment
categorized in terms of maximum intensity and the investigator’s opinion of the relationship to
the trial medication used.
RESULTS: The articles reviewed showed Asenapine was not more effective than Olazapine and
had mixed results when compared to placebo. The McIntyre 2009 3 week study showed
Asenapine to be superior to placebo in YMRS response. The McIntyre 2010 3 week study
showed Asenapine to be nonsuperior over placebo and inferior to Olanzapine in YMRS
response. The McIntyre 2009 9 week extension study showed Asenapine to be noninferior to
Olanzapine in YMRS response. Asenapine was well tolerated.
CONCLUSIONS: Based on the articles reviewed, it is unclear how effective Asenapine is in
YMRS response rates. It may be a potential option for the treatment of mania in patients
diagnosed with bipolar I disorder, but more research is needed.
KEY WORDS: Asenapine; Bipolar I Disorder; Olanzapine; Mania; Mixed state
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INTRODUCTION
Bipolar I disorder, bipolar II disorder, and cyclothymic disorder all make up the broader
spectrum known as bipolar disorder, a common and serious mental health condition.1 Bipolar I
disorder, specifically, consists of episodes of mania cycling with depression that most often
begin quickly and escalate rapidly. An episode of mania is typically defined as an abnormally
and continuously elevated, expansive, or irritable mood.1 The impact can be devastating to the
patient’s physical and psychosocial health often interfering with occupational and social
functioning and commonly leading to hospitalization. In fact, it is estimated that patients with
bipolar disorder have suicide rates 2-3 times higher than that of the general population.1 The
etiology is unknown and there are no diagnostic tests or lab studies specific for a diagnosis of
bipolar disorder. However, some risk factors have been identified. Key risk factors for bipolar
disorder include female sex, family history of the disorder, and upper socioeconomic class.
It is estimated that bipolar disorder affects over three million people in the United States
and accounts for one quarter of all mood disorders.1 The lifetime prevalence is believed to be as
high as 4%.2 Therefore, bipolar disorders cross over into many scopes of PA practice and it is
important for practitioners to be able to recognize the condition and provide proper treatment.
Although there is no national database identifying how many healthcare visits each year occur
due to bipolar disorder, it is estimated that $45 billion are spent annually on the disorder, making
it the most costly behavioral health condition in the United States.3,4
There is no cure for bipolar I disorder. Treatment entails management of acute episodes
as well as maintenance therapy. Manic episodes can be managed acutely with either lithium or
atypical antipsychotics. Atypical antipsychotics work by blocking dopamine pathways in the
brain. General side effects include blood clotting, tardive dyskinesia, significant weight gain,
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and metabolic syndrome. Consequently, insufficient tolerability has contributed to high rates of
nonadherence to treatment. Asenapine, a newer atypical antipsychotic, gained FDA approval in
2009 for the treatment of mania or mixed episodes associated with bipolar I disorder. It is
formulated as a quick dissolving sublingual tablet that is rapidly absorbed with peak plasma
concentrations occurring about one hour after administration. Current research is hopeful that
Asenapine will prove to be a superior option in both efficacy and tolerability over other available
treatments.
OBJECTIVE
The objective of this selective EBM review is to determine whether or not “Is Asenapine
more effective than other interventions in the treatment of adult patients with bipolar I disorder?”
METHODS
A detailed search was completed by the author using the key words Asenapine,
Olanzapine, bipolar I disorder, mania, and mixed state. The search engines used were OVID,
Medline, and PubMed and the articles selected were published in English and in peer-reviewed
journals from 2009-2010. Each article focused on outcomes that were of importance to the
patient (Patient Oriented Evidence that Matters, or POEMS). Randomized controlled trails
(RCTs) were searched for the following inclusion criteria: patient population 18 years old or
greater with a diagnosis of bipolar I disorder and experiencing manic or mixed episodes. Three
studies, all randomized clinical trials, were chosen comparing Asenapine to Olanzapine and/or
placebo in the treatment of mania in adult patients with bipolar I disorder. Of these studies, two
were double blind placebo-controlled, and the other was a double blind placebo-controlled
extension study. Variable dosing of Asenapine and Olanzapine was incorporated into each
study. Excluded studies were those that used Asenapine as treatment for conditions other than
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bipolar I disorder. Table 1 demonstrates the demographics of the studies included. Each study
reported statistics based on severity of manic symptoms as rated by the patient. Statistics were
reported using p-values, 95% confidence intervals (CI), relative benefit increase (RBI), absolute
benefit increase (ABI), relative risk increase (RRI), absolute risk increase (ARI), number needed
to treat (NNT), and number needed to harm (NNH).
OUTCOMES MEASURED
Outcomes measured in all of the studies included the improvement of mania severity as
reported by the patient using the Young Mania Rating Scale (YMRS). The YMRS is self report
questionnaire in which the patient rates their symptom severity in 11 different categories. These
categories include elevated mood, increased motor activity and energy, sexual interest, sleep,
irritability, speech, language-thought disorder, content, disruptive-aggressive behavior,
appearance, and insight. Symptom severity, especially in these categories, is important to the
patient; thus qualifying this outcome as a POEM. The YMRS score ranges from 0-60. Clinical
severity categories based on YMRS total score are mild (15-20), moderate (21-28), and severe
(29-44). This paper evaluates the percentage of YMRS responders, which is defined as those
experiencing greater than a 50% decrease from their baseline YMRS score upon completion of
the trial medication.
Another outcome measured was tolerability to the medications used. This was evaluated
by adverse events which were categorized based on level of intensity and the investigator’s
opinion on the relationship of the adverse event to the trial medication used. Vital signs were
assessed at each visit. Additionally, blood samples, urinalysis, electrocardiograms, body weight,
and metabolic indices were assessed throughout the trial. This paper evaluates those adverse
events labeled as a serious adverse event, or SAE.
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Table 1: Demographics and characteristics of included studies
Study
Type #
Age
Inclusion
Exclusion Criteria
Pts (yrs) Criteria
McIntyre RCT 488 18Primary Dx of Seizures; HIV+;
65+;
bipolar I
Rapid-cycling;
mean disorder;
substance abuse or
age of YMRS > 20;
dependence; positive
39.4
current manic/ stimulant screen;
mixed episode pregnant or may
(< 3 mo ago);
become pregnant;
history of 1 or use of clozapine
more moderate within 12wks;
to severe
previous trial
episodes
enrollment;
hypersensitivity to
meds used;
neuroleptic
malignant syndrome
McIntyre RCT 488 18Primary
Seizures; HIV+;
65+;
diagnosis of
Rapid-cycling;
mean bipolar I
substance abuse or
age of disorder;
dependence; positive
38.6
YMRS > 20;
stimulant screen;
current manic/ pregnant or may
mixed episode become pregnant;
(< 3 mo ago);
use of clozapine
history of 1 or within 12wks;
more moderate previous trial
to severe
enrollment;
episodes
hypersensitivity to
meds used;
neuroleptic
malignant syndrome
McIntyre RCT 504 18-73 >18 years old
Did not complete
with bipolar I
previous 3 week
disorder;
trial; rapid cycling
experiencing
mood course;
manic/mixed
substance abuse or
episodes;
dependence;
completed a
imminent risk of
previous 3
harm to self or
week trial;
others; unlikely to
continued
comply
treatment
could be of
clinical benefit

W/D

Interventions

152

Asenapine
SL (10 mg
BID day one,
5 or 10 mg
BID
thereafter);
Oral
olanzapine
(15 mg QD
on day one,
5, 10,15, 20
mg QD
thereafter);
matched
placebo
Asenapine
SL (10 mg
BID day one,
5 or 10 mg
BID
thereafter);
Oral
olanzapine
(15 mg QD
on day one,
5,10,15, or
20 mg QD
thereafter;
matched
placebo
Asenapine
SL (10 mg
BID on day
one, 5 or 10
mg BID
thereafter);
Oral
olanzapine
(15 mg QD
day one,
5,10,15,20
mg QD
thereafter)

146

195
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RESULTS
This EBM review was done on three randomized controlled trials; two of which were
three week comparative trials, and the other a nine week extension study. Each article used
dichotomous data when presenting outcomes. The dosing of medications was the same in each
trial study. The dosing was as follows: sublingual Asenapine (10 mg BID on day 1, followed by
5 or 10 mg BID thereafter) and oral Olanzapine (15 mg BID on day 1, followed by 5, 10, 15, or
20 mg QD thereafter). Visually matched placebo was incorporated into both 3 weeks studies,
but it was not included in the 9 week extension study. The primary efficacy measured in all of
the studies was the change in the YMRS score. This review focuses on YMRS responders which
are defined as those having a > 50% reduction from baseline YMRS score at study endpoint. All
patients that participated in the study had a primary diagnosis of bipolar I disorder and were
currently experiencing manic or mixed episodes. All patients were 18 years of age or older.
It is important to understand the statistical calculations that were used to evaluate the
articles selected. The percentage of YMRS responders was considered for the efficacy rate for
each intervention, with Asenapine being the Experimental Event Rate (EER) and Olanzapine or
placebo being the Controlled Event Rate (CER). The EER and CER can be used to calculate the
Relative Benefit Increase (RBI) and Absolute Benefit Increase (ABI). The ABI, which is the
absolute arithmetic difference in rates of good outcomes between the experimental and control
groups, can then be used to calculate the Numbers Needed to Treat (NNT). The NNT tells the
practitioner the number of patients that need to be treated in order to obtain one additional good
outcome as compared to the control medication.
In the McIntyre, 2009 three week study, 488 patients with a mean age of 39.4 years old
enrolled in the study.2 The YMRS score was assessed at baseline, days 2, 4, 7, 14, and study
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endpoint (day 21). In order to qualify for the study, patients had to have a baseline YMRS score
> 20. Trial completion rates were 62.9%, 61.5%, and 79.6% for Asenapine-, placebo-, and
Olanzapine-treated patients, respectively. YMRS response was analyzed using Pearson chisquare tests, with last observation carried forward (LOCF). All participants were randomly
allocated into either an experimental group (Asenapine) or a control group (Olanzapine or
placebo). The percentage of YMRS responders for Asenapine versus placebo were 42.3% and
25.2%, respectively. Asenapine showed a greater response over placebo, and the data is
considered clinically significant with a p-value < 0.01. The NNT calculated for Asenapine
versus placebo was 6 (95% CI: 3 to 17). The percentage of YMRS responders for Asenapine
versus Olanzapine were 42.3% and 50.0%, respectively, and the NNT value was -13. However,
the trial included Olanzapine as a way to assess assay sensitivity in the event that outcomes
measured between Asenapine and placebo were not significantly different. Therefore, no pvalue or 95% CI was available comparing Asenapine and Olanzapine. The results are
summarized in Table 2 and Table 3.
In the McIntyre, 2010 three week study, 488 patients with a mean age of 38.6 years old
enrolled in the study.3 This study shared many of the same characteristics as the McIntyre 2009
three week study, such as required baseline YMRS > 20, YMRS responder analysis using
Pearson chi-square tests and LOCF, and Olanzapine included to assess assay sensitivity.
However, this study performed a post hoc analysis comparing YMRS response rates for
Asenapine and Olanzapine on day 21. Trial completion rates were 67.0%, 58.2%, and 78.5% for
Asenapine-, placebo-, and Olanzapine-treated patients, respectively. The percentage of YMRS
responders for Asenapine versus placebo were 42.6% and 34.0%, respectively. Asenapine did
not significantly differ from placebo (p-value > 0.05), and the NNT is 12 (95% CI: -∞ to -29 and
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4 to ∞). The percentage of YMRS responders for Asenapine versus Olanzapine were 42.6% and
54.7%, respectively, and the NNT value was -9. Post hoc analysis showed YMRS response rates
with Olanzapine to be significantly greater than those with Asenapine (p-value < 0.05). The
results are summarized in Table 2 and Table 3.
In the McIntyre, 2009 nine week extension study, Asenapine and Olanzapine were
directly compared.4 Completion of a prior three week trial was required to participate in the
additional nine week extension study. Upon initiation of the trial, there was no rerandomization
or identification of prior treatment groups. Those receiving placebo were blindly switched to
Asenapine, but were only included in the safety analysis. A total of 504 patients enrolled in the
trial, and completion rates were 62%, 53%, and 64% for Asenapine-, placebo/Asenapine-, and
Olanzapine-treated patients, respectively. YMRS response rates at day 84 were 90% and 92%
with Asenapine and Olanzapine, respectively. These rates are not significantly different (pvalue >0.05), and the NNT is -50. The results are summarized in Table 3.

Table 2: Asenapine vs. Placebo on YMRS response
Asenapine
Placebo
p-value
(EER)
(CER)
McIntyre,
2009 (3
42.3%
25.2%
<0.01
weeks)
McIntyre,
2010 (3
42.6%
34.0%
>0.05
weeks)
a
95% CI: 3 to 17
b
95% CI: -∞ to -29 and 4 to ∞

RBI

ABI

NNT

0.68

0.171

6a

0.25

0.086

12b
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Table 3: Asenapine vs. Olanzapine on YMRS response
Asenapine Olanzapine
p-value
(EER)
(CER)
McIntyre,
2009 (3
42.3%
50.0%
NA
weeks)
McIntyre,
2010 (3
42.6%
54.7%
<0.05a
weeks)
McIntyre,
2009 (9
92.0%
90.0%
>0.05
week
extension)
a
based on post hoc analysis conducted at day 21

RBI

ABI

NNT

-0.15

-0.077

-13

-0.26

-0.120

-9

-0.02

-0.020

-50

This review also looked at safety and tolerability outcomes as measured by the
percentage of treatment-emergent serious adverse events, or SAE. All three trials reviewed in
this paper provided percentages of SAE, and these values were used to calculate relative and
absolute risk increases (RRI and ARI), which in turn are used to calculate the Number Needed to
Harm (NNH). The NNH can tell a practitioner how many patients can be treated with the
experimental treatment over the control treatment before one patient will be harmed. Table 4
and Table 5 summarize the safety and tolerability data from the articles reviewed. There were
no p-values or CI values available for this data.

Table 4: Serious Adverse Event Data for Asenapine vs. Placebo
Asenapine
Placebo
RRI
(EER)
(CER)
McIntyre,
2009 (3
4.10%
6.70%
-0.39
weeks)
McIntyre,
2010 (3
6.50%
7.10%
-0.08
weeks)

ARI

NNH

-0.026

-37

-0.006

-167
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Table 5: Serious Adverse Event Data for Asenapine vs. Olanzapine
Asenapine
Olanzapine
RRI
(EER)
(CER)
McIntyre,
2009 (3
4.10%
3.71%
0.66
weeks)
McIntyre,
2010 (3
6.50%
3.90%
0.66
weeks)
McIntyre,
2009 (9 week
12.0%
10.0%
0.20
extension)

ARI

NNH

0.004

250

0.026

39

0.020

50

DISCUSSION
Atypical antipsychotics have proven to be effective in the treatment of mania in bipolar
patients, and their use in practice has increased considerably. Asenapine (Saphris®) is a newer
atypical antipsychotic which gained FDA approval in 2009. It is approved in the United States
for use in both schizophrenia and acute mania associated with bipolar disorder. The FDA issued
a black box warning for elderly patients with dementia-related psychosis due to increase risk of
stroke or death with Asenapine. Research is currently underway to determine how effective and
tolerable Asenapine will be compared to other atypical antipsychotics and other treatment
options.
The randomized controlled trials in this review demonstrated mixed results in terms of
efficacy rates for Asenapine versus Olanzapine or placebo, and it is clear that additional research
is needed to determine how effective Asenapine may be in the treatment of mania in bipolar
patients.
The studies used in this review were not without limitations. In patients with bipolar
disorder, nonadherence to treatment and concomitant medication use are significant concerns and
can complicate trial results. The duration of the studies used in this review ranged from three
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weeks to twelve weeks which is not an adequate amount of time to influence clinical decision
making for a chronic mental health condition such as bipolar disorder. Additionally, the
outcome used to measure efficacy (YMRS response) was assessed at one single point in time
limiting the interpretation of data. In both three week trials, Olanzapine was used to assess assay
sensitivity; therefore, comparisons between Olanzapine and Asenapine need to be interpreted
with caution.2,3
CONCLUSION
The studies reviewed show that Asenapine is not more effective than Olanzapine, and the
results were mixed regarding superiority of Asenapine over placebo. Asenapine may be an
effective and tolerable option for treating mania in bipolar patients; although, the varying results
in each article indicate more research is needed to establish more certain efficacy rates. The
2009 3-week study showed Asenapine to be superior to placebo. The 2010 3-week study showed
that Asenapine was not clinically superior to placebo in YMRS response; however, the primary
outcome measured in this article (least squares mean changes in YMRS score) did show
superiority with Asenapine. The 2009, 9 week extension study had the longest duration and
perhaps the most promising results for Asenapine which was found to be noninferior to
Olanzapine and well tolerated. None of the studies included in this review proved Asenapine to
be superior over Olanzapine in efficacy.
It is important to remember that bipolar I disorder is a chronic condition that typically
requires lifelong therapy. Longer duration studies are needed to help understand the role
Asenapine may play in treatment. Asenapine is a relatively new drug (FDA approved in 2009)
and limited studies have been published to date regarding its use in bipolar disorder. Studies that
utilize a more controlled setting that would limit concomitant medication use and nonadherence
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to treatment would be beneficial. Additionally, incorporating patients experiencing rapid cycling
bipolar disorder could provide insight since these patients typically have a more refractory
course of illness. Another point of interest that is worth reviewing is route of administration.
Asenapine was developed as a sublingual tablet which could be beneficial to those with manic
episodes having trouble swallowing medication.
In conclusion, the articles in this review had mixed results regarding the efficacy rates of
Asenapine as measured by YMRS response. More research is needed to clarify how to
incorporate Asenapine into the clinical management of bipolar I patients experiencing manic
episodes.
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